JAK2 and acquired polycythemia vera: These data suggested that despite inflammatory microenvironment and JAK2 V617F oncogene-driven myeloproliferation, certain mechanisms must mitigate the potential genotoxic impact of the overall oncogenic program controlled by JAK2 V617F, thereby allowing for PV chronic proliferation with relatively stable genome.